Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

QURE

uniQure N.V

Mar 06 • 04:00PM ET

14.27

+3.62 33.99 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: SRPT BLUE CRSP BMRN NTLA SGMO RCKT EDIT ADVM BOLD

| Held by: XBI VXF IBB SCHA LABU JGRO KOMP ITOT SURI SCHB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.48	Insider Own	9.97%	Shs Outstand	62.34M	Perf Week	-8.70%
Market Cap	879.09M	Forward P/E	-	EPS next Y	-3.12	Insider Trans	-6.87%	Shs Float	55.46M	Perf Month	-46.45%
Enterprise Value	793.14M	PEG	-	EPS next Q	-0.87	Inst Own	97.87%	Short Float	19.34%	Perf Quarter	-44.00%
Income	-198.97M	P/S	54.60	EPS this Y	-2.89%	Inst Trans	9.93%	Short Ratio	3.56	Perf Half Y	-19.51%
Sales	16.10M	P/B	4.47	EPS next Y	12.50%	ROA	-28.81%	Short Interest	10.73M	Perf YTD	-40.37%
Book/sh	3.19	P/C	1.41	EPS next 5Y	-1.10%	ROE	-207.10%	52W High	71.50 -80.04%	Perf Year	14.07%
Cash/sh	10.11	P/FCF	-	EPS past 3/5Y	-8.45% -4.24%	ROIC	-27.20%	52W Low	7.76 83.89%	Perf 3Y	-31.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-46.73% -15.57%	Gross Margin	-2.16%	Volatility	22.53% 13.39%	Perf 5Y	-56.07%
Dividend TTM	-	EV/Sales	49.26	EPS Y/Y TTM	29.32%	Oper. Margin	-1202.09%	ATR (14)	2.73	Perf 10Y	1.78%
Dividend Ex-Date	-	Quick Ratio	10.43	Sales Y/Y TTM	-40.64%	Profit Margin	-1236.00%	RSI (14)	39.62	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	10.43	EPS Q/Q	60.34%	SMA20	-27.93%	Beta	0.83	Target Price	28.67
Payout	-	Debt/Eq	2.70	Sales Q/Q	6.65%	SMA50	-35.64%	Rel Volume	4.59	Prev Close	10.65
Employees	221	LT Debt/Eq	2.68	Earnings	Mar 02 BMO	SMA200	-43.12%	Avg Volume	3.01M	Price	14.27
IPO	Feb 05, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	37.63% 4.49%	Trades		Volume	13,833,954	Change	33.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-03-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$15
Mar-03-26	Downgrade	Mizuho	Outperform → Neutral	$12
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11
Mar-02-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$9
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-28-26	Initiated	Barclays	Equal Weight	$31
Nov-04-25	Downgrade	William Blair	Outperform → Mkt Perform
Aug-14-25	Upgrade	Mizuho	Neutral → Outperform	$30
Apr-01-25	Resumed	Chardan Capital Markets	Buy	$38
Dec-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-10-24	Resumed	Raymond James	Outperform	$20
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8
Dec-19-23	Downgrade	Mizuho	Buy → Neutral	$52 → $10
Mar-17-22	Upgrade	UBS	Neutral → Buy	$40
Jun-15-21	Initiated	BTIG Research	Buy	$46
May-21-21	Initiated	UBS	Neutral	$40
Apr-26-21	Resumed	Credit Suisse	Outperform	$78
Apr-01-21	Upgrade	Mizuho	Neutral → Buy	$52
Jan-07-21	Upgrade	Guggenheim	Neutral → Buy	$62
Nov-24-20	Initiated	H.C. Wainwright	Buy	$80

Show Previous Ratings

Mar-06-26 07:13PM	FDA Vaccine Chief Vinay Prasad Set to Leave Post Next Month (Bloomberg) +33.99%
09:57AM	QURE Stock Crashes 32% in a Week: Here's What You Should Know (Zacks)
Mar-05-26 06:01PM	Federal Health Officials Attack Rare-Disease Drug, Say Company Lied (The Wall Street Journal) +17.81%
12:11PM	FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial (Benzinga)
Mar-04-26 09:58AM	What's Going On With uniQure Stock Wednesday? (Benzinga)
09:35AM	Loading…
09:35AM	uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-26 11:38AM	uniQure downgraded after FDA backs sham-controlled trial for Huntingtons therapy (Investing.com) -14.00%
09:33AM	MongoDB downgraded, Block upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More (24/7 Wall St.)
Mar-02-26 04:37PM	Stocks Recover as Iran War Pushes Energy and Defense Stocks Higher (Barchart) -32.82%
04:28PM	Uniqure Plummets By A Third After Realizing 'The Worst Case Scenario' For Its Gene Therapy (Investor's Business Daily)
02:01PM	uniQure NV (QURE) Q4 2025 Earnings Call Highlights: Breakthroughs and Challenges in Gene Therapy (GuruFocus.com)
12:57PM	FDA tells uniQure to conduct another study of Huntingtons gene therapy (Clinical Trials Arena)
12:33PM	uniQure N.V. Q4 2025 Earnings Call Summary (Moby)
11:37AM	UniQure Stock Drops 36% After Earnings. Bad News From the FDA Gets Even Worse. (Barrons.com)
11:19AM	Loading…
11:19AM	Markets Rebound After Initial Selloff Triggered by Middle East Tensions (Barchart)
10:37AM	uniQure Q4 Earnings Call Highlights (MarketBeat)
08:58AM	Uniqure Plummets More Than 40% On Another Twist In Its Gene Therapy Saga (Investor's Business Daily)
08:51AM	uniQure Stock Plunges 40% After FDA Shocker (Benzinga)
08:20AM	uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	UniQure: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces 2025 Financial Results and Provides Recent Company Updates (GlobeNewswire)
07:00AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Feb-28-26 02:21AM	Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating (Insider Monkey)
Feb-27-26 12:49AM	QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? (New feeds test provider finance) -8.68%
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily) -31.18%
09:55AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-23-26 07:05AM	uniQure to Announce 2025 Financial Results (GlobeNewswire)
Feb-18-26 09:00AM	uniQure N.V. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights - QURE (PR Newswire) +7.72%
Feb-14-26 01:28AM	UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity (Insider Monkey)
01:11AM	Loading…
Feb-13-26 01:11AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire) -8.36%
Feb-12-26 08:00AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights QURE (Business Wire) -7.22%
Feb-06-26 01:58PM	Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch (Benzinga)
07:05AM	uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Feb-02-26 09:35AM	uniQure (QURE) Navigates Gene Therapy Development as Investors Weigh Long-Term Potential (Insider Monkey) +8.71%
Jan-20-26 09:01AM	Here's Why uniQure (QURE) Fell in Q3 (Insider Monkey)
Jan-12-26 10:11AM	Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? (Insider Monkey) -9.00%
Jan-09-26 01:14PM	uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT-130 Approval Pathway (Benzinga) +9.37%
07:05AM	uniQure Announces Type A Meeting Scheduled with FDA (GlobeNewswire)
Dec-21-25 09:56AM	What Do Analysts Think About UniQure (QURE)? (Insider Monkey)
Dec-15-25 11:11PM	UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch (Insider Monkey) +7.15%
Dec-04-25 12:18PM	uniQure N.V. (QURE): A Bear Case Theory (Insider Monkey) -10.75%
10:02AM	UniQure Plummets, Again, As FDA Indicates It Will Reject Huntington's Gene Therapy (Investor's Business Daily)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Nov-25-25 08:39AM	William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty (Insider Monkey)
Nov-19-25 08:16AM	Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 (Insider Monkey) -5.92%
Nov-17-25 12:15PM	Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA (Insider Monkey)
Nov-12-25 07:00AM	uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences (Insider Monkey)
Nov-10-25 04:01PM	uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges (GuruFocus.com) -5.90% +17.93%
08:15AM	uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:14AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:05AM	uniQure to Announce Third Quarter 2025 Financial Results (GlobeNewswire) +5.56%
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily) -14.39%
Nov-04-25 01:36PM	FDA halts uniQures plans for Huntingtons disease gene therapy (Pharmaceutical Technology) -11.23%
Nov-03-25 04:29PM	These Stocks Moved the Most Today: Kenvue, Kimberly-Clark, Amazon, uniQure, Palantir, Idexx, Cipher Mining, and More (Barrons.com) -49.34%
04:27PM	UniQure Plummets 49% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy (Investor's Business Daily)
11:15AM	uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results (Insider Monkey)
08:33AM	UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. (Barrons.com)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Oct-30-25 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 10:00AM	uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 08:16AM	Breakout Momentum Plays You Need to Know About (MarketBeat)
Oct-22-25 04:58PM	uniQure N.V. (QURE): A Bull Case Theory (Insider Monkey) -5.01%
Oct-19-25 03:09AM	H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating (Insider Monkey)
Oct-13-25 05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-08-25 05:34AM	Jim Cramer on uniQure: "This One Has Too Many Questions for Me Up Here" (Insider Monkey)
Oct-03-25 04:14PM	QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop (MarketBeat)
Sep-30-25 12:46PM	uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission (Insider Monkey)
Sep-29-25 06:28PM	uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment (Insider Monkey) +9.37%
04:05PM	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Sep-25-25 11:38PM	uniQure Announces Pricing of Upsized $300 Million Public Offering (GlobeNewswire) +10.84%
11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:23AM	Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington's Disease (Insider Monkey)
09:36AM	Stocks to Watch Thursday: Intel, Oracle, CarMax, Accenture (The Wall Street Journal)
09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
06:24AM	Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? (Zacks)
Sep-24-25 04:37PM	Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it (MarketWatch) +247.73%
04:21PM	A Cure For Huntington's Disease? UniQure Launches Nearly 250%. (Investor's Business Daily)
04:06PM	uniQure Announces $200 Million Proposed Public Offering (GlobeNewswire)
10:23AM	uniQure Stock Doubles On Promising Data From Huntington's Disease Trial (Benzinga)
07:10AM	uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding (GlobeNewswire)
07:05AM	uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-05-25 07:05AM	uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Jul-31-25 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet (Zacks)
Jul-29-25 08:15AM	uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -8.68%
07:13AM	UniQure: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress (GlobeNewswire)
Jul-22-25 07:05AM	uniQure to Announce Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-23-25 01:38AM	Lake Street: AMT-130 Could Be Game-Changer For ClearPoint (Insider Monkey)
Jun-11-25 08:00AM	uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer (GlobeNewswire)
Jun-04-25 08:55AM	Lake Street says AMT-130 could be significantly impactful for ClearPoint (TipRanks)
Jun-02-25 07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
May-29-25 07:05AM	uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) (GlobeNewswire)
May-21-25 09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +7.37%
May-14-25 09:55AM	Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? (Zacks)
May-10-25 03:04AM	uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... (GuruFocus.com)
May-09-25 08:20AM	UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapusta Matthew C	CEO, Managing Director	Mar 04 '26	Sale	9.06	14,581	132,104	660,658	Mar 06 05:07 PM
Abi-Saab Walid	Chief Medical Officer	Mar 04 '26	Sale	9.06	808	7,320	189,669	Mar 06 04:59 PM
Potts Jeannette	Chief Legal Officer	Mar 04 '26	Sale	9.06	3,412	30,913	138,483	Mar 06 04:35 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 04 '26	Sale	9.06	12,000	108,720	226,581	Mar 06 04:30 PM
Potts Jeannette	Officer	Mar 04 '26	Proposed Sale	9.06	3,412	30,927		Mar 04 04:56 PM
KLEMT CHRISTIAN	Officer	Mar 04 '26	Proposed Sale	9.06	12,000	108,770		Mar 04 04:50 PM
Kapusta Matthew C	Director	Mar 04 '26	Proposed Sale	9.06	14,581	132,165		Mar 04 04:46 PM
Kapusta Matthew C	CEO, Managing Director	Mar 02 '26	Sale	9.95	34,437	342,648	604,639	Mar 04 04:42 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 02 '26	Sale	9.95	12,532	124,693	198,981	Mar 04 04:36 PM
Potts Jeannette	Chief Legal Officer	Mar 02 '26	Sale	9.95	8,578	85,351	106,495	Mar 04 04:31 PM
Abi-Saab Walid	Chief Medical Officer	Mar 02 '26	Sale	9.95	1,660	16,517	148,777	Mar 04 04:25 PM
Kapusta Matthew C	Director	Mar 02 '26	Proposed Sale	9.95	34,437	342,586		Mar 02 05:39 PM
KLEMT CHRISTIAN	Officer	Mar 02 '26	Proposed Sale	9.95	12,832	127,655		Mar 02 05:29 PM
Potts Jeannette	Officer	Mar 02 '26	Proposed Sale	9.95	8,578	85,336		Mar 02 05:23 PM
Kapusta Matthew C	CEO, Managing Director	Feb 25 '26	Sale	23.86	12,378	295,339	639,076	Feb 27 04:49 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 25 '26	Sale	23.86	6,217	148,338	211,513	Feb 27 04:42 PM
Kapusta Matthew C	Director	Feb 25 '26	Proposed Sale	23.86	12,378	295,307		Feb 25 04:07 PM
KLEMT CHRISTIAN	Officer	Feb 25 '26	Proposed Sale	23.86	6,217	148,321		Feb 25 04:01 PM
Gut Robert	Director	Jan 12 '26	Option Exercise	14.08	17,810	250,765	57,955	Jan 14 04:26 PM
Gut Robert	Director	Jan 12 '26	Sale	24.62	25,613	630,483	32,342	Jan 14 04:26 PM
Kaye Jack	Director	Jan 09 '26	Option Exercise	19.39	6,390	123,902	26,829	Jan 12 04:21 PM
Kaye Jack	Director	Jan 09 '26	Sale	27.28	6,390	174,319	20,439	Jan 12 04:21 PM
Gut Robert	Director	Jan 12 '26	Proposed Sale	26.42	25,613	676,695		Jan 12 03:59 PM
Kaye Jack	Director	Jan 09 '26	Proposed Sale	27.28	6,390	174,330		Jan 09 03:59 PM
Gut Robert	Director	Nov 06 '25	Option Exercise	4.57	15,840	72,389	71,579	Nov 10 04:54 PM
Gut Robert	Director	Nov 06 '25	Sale	27.26	31,434	856,881	40,145	Nov 10 04:54 PM
Kaye Jack	Director	Nov 04 '25	Option Exercise	9.88	38,810	383,535	38,249	Nov 06 05:01 PM
Kaye Jack	Director	Nov 04 '25	Sale	30.34	38,810	1,177,517	20,439	Nov 06 05:01 PM
Gut Robert	Director	Nov 06 '25	Proposed Sale	26.06	31,434	819,170		Nov 06 04:13 PM
Kaye Jack	Director	Nov 04 '25	Proposed Sale	34.29	38,810	1,330,794		Nov 04 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Option Exercise	6.52	226,316	1,474,909	877,770	Sep 26 07:43 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Sale	41.46	226,316	9,382,473	651,454	Sep 26 07:43 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Option Exercise	5.37	15,000	80,550	232,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Option Exercise	13.03	3,000	39,090	220,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Sale	55.00	15,000	825,000	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Sale	40.04	3,000	120,120	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Officer	Sep 26 '25	Proposed Sale	55.00	15,000	825,000		Sep 26 04:04 PM
KLEMT CHRISTIAN	Officer	Sep 24 '25	Proposed Sale	40.00	3,000	120,000		Sep 24 08:01 PM
Kapusta Matthew C	Director	Sep 24 '25	Proposed Sale	41.45	226,316	9,381,750		Sep 24 07:59 PM
Abi-Saab Walid	Chief Medical Officer	Jun 27 '25	Sale	13.92	1,466	20,407	150,437	Jul 01 04:49 PM
Springhorn Jeremy P.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,694	Jun 24 06:08 PM
POST LEONARD E	Director	Jun 20 '25	Sale	14.45	2,112	30,518	29,937	Jun 24 06:03 PM
Kaye Jack	Director	Jun 20 '25	Sale	14.45	2,112	30,518	20,439	Jun 24 05:53 PM
Jacques Rachelle Suzanne	Director	Jun 20 '25	Sale	14.45	2,112	30,518	28,346	Jun 24 05:50 PM
Gut Robert	Director	Jun 20 '25	Sale	14.45	3,336	48,205	56,879	Jun 24 05:45 PM
Balachandran Madhavan	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,697	Jun 24 05:42 PM
Meek David D.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	34,190	Jun 24 05:34 PM
Potts Jeannette	Chief Legal Officer	Jun 16 '25	Sale	15.14	4,670	70,704	115,073	Jun 20 07:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QURE

uniQure N.V

Upgrade your FINVIZ experience